4SC's resminostat receives Orphan Drug Designation from the European ...
4SC AG received EMA's Orphan Drug Designation for resminostat, treating CTCL, a rare disease affecting 5,000 Europeans annually. Resminostat showed significant efficacy in the RESMAIN study, improving progression-free survival. ODD grants 10 years' EU market exclusivity, aiding 4SC's commercialization efforts in major markets.
Reference News
4SC's resminostat receives Orphan Drug Designation from the European ...
4SC AG received EMA's Orphan Drug Designation for resminostat, treating CTCL, a rare disease affecting 5,000 Europeans annually. Resminostat showed significant efficacy in the RESMAIN study, improving progression-free survival. ODD grants 10 years' EU market exclusivity, aiding 4SC's commercialization efforts in major markets.